Adimab Reports 11 New Clinical Programs in 2025, Reaching 89 Total Programs with Six Approved Therapies
核心洞察
Adimab (搜索) announced 11 new partner programs entered clinical trials in 2025, bringing the total number of clinical programs to 89 since 2009.
Six therapeutic products containing Adimab (搜索)-discovered or optimized molecules have received commercial approval, including GSK's Exdensur (搜索) for severe asthma (搜索).
The company's antibody discovery platform has generated over 650 therapeutic programs across partnerships with more than 140 pharmaceutical and biotechnology companies.
Adimab (搜索), LLC, the global leader in therapeutic antibody discovery and engineering, announced significant growth in its clinical pipeline with 11 new programs entering clinical trials in 2025. This milestone brings the total number of partner programs that have entered clinical trials to 89, while six therapeutic products containing molecules discovered or optimized using the Adimab platform have received commercial authorization.
Recent Approvals Drive Commercial Success
The latest partner program to receive approval is GSK's Exdensur (搜索) (depemokimab), which was approved in the United States for treating severe asthma (搜索) with an eosinophilic phenotype and in the UK and Japan for severe asthma and chronic rhinosinusitis with nasal polyps (搜索) (CRSwNP).
The growing portfolio of approved products demonstrates the clinical viability of Adimab (搜索)'s antibody discovery platform. Other commercial products include Innovent (搜索)'s TYVYT (sintilimab injection), a PD-1 (搜索) program approved in China for multiple cancer treatments, and SINTBILO (搜索) (tafolecimab injection), a PCSK9 program for hypercholesterolemia (搜索) and mixed dyslipidemia (搜索). Additional approvals include IASO Bio (搜索)'s FUCASO (搜索) (equecabtagene autoleucel), a BCMA (搜索) CAR-T therapy for multiple myeloma (搜索) in China, Invivyd's PEMGARDA (pemivibart) for COVID-19 (搜索) prophylaxis in the United States, and Sun Pharma's UNLOXCYT (搜索) (cosibelimab), a PD-L1 (搜索) program for cutaneous squamous cell carcinoma (搜索).
Expanding Partnership Network
Partners with new clinical programs in 2025 include Abogen (搜索), GSK, iTeos (搜索), Innovent (搜索), Invivyd, Kelonia Therapeutics (搜索), and Triveni Bio (搜索). The company's partnership model continues to expand, with 10 partners exercising commercial options in 2025, including Bambusa, Biogen, Ikaika, Meiji Seika Pharma, Montis Biosciences, Novartis, SixPeaks Bio, and Werewolf.
"We are awed by the incredible work our partners do in developing these molecules and bringing them to market to benefit patients around the world, and it is gratifying to realize that we have played a role in that process," said Philip T. Chase, Chief Executive Officer of Adimab (搜索).
Technology Platform and Capabilities
Adimab (搜索)'s integrated platform encompasses multiple therapeutic modalities through its proprietary yeast-based technology. The company discovers therapeutic antibodies in IgG and VHH formats, utilizing fully human synthetic diversity and additional diversities from in vivo sources. These antibodies demonstrate exquisite specificity and are utilized in monoclonal and multispecific formats, CAR-T therapies, antibody-drug conjugates, and other modalities.
The company's engineering capabilities have been refined through thousands of lead antibody optimization efforts, focusing on potency, specificity, and developability. Adimab (搜索) also offers extensive bispecific and multispecific expertise, including proprietary solutions for Fc and Fab heterodimerization, enabling numerous product designs with excellent developability properties.
Revenue Structure and Future Outlook
The establishment of Adimab (搜索) Royalty Company (ARC) in 2024 has created a distinct business unit housing royalties from nearly 500 completed therapeutic programs. "This first wave of approvals generating revenue for Adimab Royalty Company is exactly what we envisioned when we created this structure in 2024," said Ryan McGovern, Chief Financial Officer of Adimab.
Since 2009, Adimab (搜索) has partnered with over 140 pharmaceutical and biotechnology companies, generating more than 650 therapeutic programs. The company's technology has been transferred and implemented at major pharmaceutical companies including GSK, Biogen, Novo Nordisk, Merck, Lilly, and Takeda. Numerous additional Adimab-associated programs are currently in pivotal Phase II or Phase III clinical trials, suggesting continued growth in the approval pipeline.